Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer

Journal of Clinical Investigation

Volumn 124, Issue 11, 2014, Pages 5013-5026

  Qin, Jun ^a,b   Lee, Hui Ju ^b   Wu, San Pin ^b,c   Lin, Shih Chieh ^b   Lanz, Rainer B ^b   Creighton, Chad J ^b   DeMayo, Francesco J ^b   Tsai, Sophia Y ^b   Tsai, Ming Jer ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR RECEPTOR COACTIVATOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; NCOA2 PROTEIN, MOUSE; PTEN PROTEIN, MOUSE;

ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER TISSUE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MOUSE; MURINE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DISEASE COURSE; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SECONDARY; TRANSGENIC MOUSE; TUMOR CELL LINE; UPREGULATION;

ANDROGENS; ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR RECEPTOR COACTIVATOR 2; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PTEN PHOSPHOHYDROLASE; UP-REGULATION;

EID: 84908610652     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76412     Document Type: Article

References (50)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, Georgia, USA: American Cancer Society; 2010.
2. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24(18):1967-2000.
3. Wang S, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4(3):209-221.
4. Chen Z, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436(7051):725-730.
5. Tomlins SA, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-648.
6. Lei Q, et al. NKX3.1 stabilizes p53, inhibits AKT activation, blocks prostate cancer initiation caused by PTEN loss. Cancer Cell. 2006;9(5):367-378.
7. Carver BS, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41(5):619-624.
8. King JC, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41(5):524-526.
9. Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
10. Tomlins SA, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39(1):41-51.
11. Trotman LC, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1(3):E59.
12. Ding Z, et al. SMAD4-dependent barrier constrains prostate cancer growth metastatic progression. Nature. 2011;470(7333):269-273.
13. Qin J, et al. COUP-TFII inhibits TGF-betainduced growth barrier to promote prostate tumorigenesis. Nature. 2013;493(7431):236-240.
14. Chen M, et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell. 2011;20(2):173-186.
15. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med. 2007;357(26):2696-2705.
16. Macfarlane RJ, Chi KN. Research in castrationresistant prostate cancer: What does the future hold? Curr Oncol. 2010;17(suppl 2):S80-S86.
17. Carver BS, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575-586.
18. Mulholland DJ, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011;19(6):792-804.
19. Mulholland DJ, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012;72(7):1878-1889.
20. Matsumoto H, et al. Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability. Cancer Res. 2013;73(16):5206-5217.
21. Gehin M, Mark M, Dennefeld C, Dierich A, Gronemeyer H, Chambon P. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 p/CIP. Mol Cell Biol. 2002;22(16):5923-5937.
22. Chopra AR, et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science. 2008;322(5906):1395-1399.
23. Chopra AR, et al. Cellular energy depletion resets whole-body energy by promoting coactivatormediated dietary fuel absorption. Cell Metab. 2011;13(1):35-43.
24. Reineke EL, et al. SRC-2 coactivator deficiency decreases functional reserve in response to pressure overload of mouse heart. PLoS One. 2013;7(12):e53395.
25. Stashi E, et al. SRC-2 is an essential coactivator for orchestrating metabolism circadian rhythm. Cell Rep. 2014;6(4):633-645.
26. Agoulnik IU, et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006;66(21):10594-10602.
27. Jin C, McKeehan K, Wang F. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate. 2003;57(2):160-164.
28. Tuveson DA, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation widespread neoplastic developmental defects. Cancer Cell. 2004;5(4):375-387.
29. Creighton CJ. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS One. 2008;3(3):e1816.
30. Nakagawa T, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One. 2008;3(5):e2318.
31. Brognard J, Newton AC. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab. 2008;19(6):223-230.
32. Pei H, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009;16(3):259-266.
33. Suzuki A, Nakano T, Mak TW, Sasaki T. Portrait of PTEN: messages from mutant mice. Cancer Sci. 2008;99(2):209-213.
34. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247-269.
35. Ebi H, et al. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci USA. 2013;110(52):21124-21129.
36. Pandiella A, Montero JC. Molecular pathways: P-Rex in cancer. Clin Cancer Res. 2013;19(17):4564-4569.
37. Fine B, et al. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science. 2009;325(5945):1261-1265.
38. Uhlenhaut NH, et al. Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol Cell. 2012;49(1):158-171.
39. Chinenov Y, Sacta MA, Cruz AR, Rogatsky I. GRIP1-associated SET-domain methyltransferase in glucocorticoid receptor target gene expression. Proc Natl Acad Sci USA. 2008;105(51):20185-20190.
40. Wu SP, Lee DK, Demayo FJ, Tsai SY, Tsai MJ. Generation of ES cells for conditional expression of nuclear receptors and coregulators in vivo. Mol Endocrinol. 2010;24(6):1297-1304.
41. Park JH, et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol. 2002;161(2):727-735.
42. Xie X, Qin J, Lin SH, Tsai SY, Tsai MJ. Nuclear receptor chicken ovalbumin upstream promoter- transcription factor II (COUP-TFII) modulates mesenchymal cell commitment and differentiation. Proc Natl Acad Sci USA. 2011;108(36):14843-14848.
43. Qin J, Chen X, Xie X, Tsai MJ, Tsai SY. COUPTFII regulates tumor growth and metastasis by modulating tumor angiogenesis. Proc Natl Acad Sci USA. 2010;107(8):3687-3692.
44. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43-49.
45. Creighton CJ, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One. 2012;7(3):e34546.
46. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
47. Luo J, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137(5):835-848.
48. Creighton CJ, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106(33):13820-13825.
49. Creighton CJ, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008;26(25):4078-4085.
50. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.